2:19 PM
 | 
Dec 01, 2017
 |  BC Extra  |  Company News

Akouos in-licenses gene therapy vectors from Mass. Eye and Ear

Newco Akouos Inc. (Boston, Mass.) acquired an exclusive license to a vector platform to develop gene therapies for hearing and balance disorders from Massachusetts Eye and Ear (Boston, Mass.) and Lonza Group Ltd. (SIX:LONN). The license includes sublicensing rights.

The platform includes 40,000 in silico-designed ancestral adeno-associated virus (AAV) vectors developed by Luk Vandenberghe at Massachusetts Eye and Ear.

Concurrently, Akouos raised $7.5 million...

Read the full 303 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >